Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy ( Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 36, (13568-13573) DOI: 10.1073/pnas.0806268105);Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 36, 2008, Pages 13568-13573

  Shibata, Tatsuhiro ^a   Ohta, Tsutomu ^a   Tong, Kit I ^b   Kokubu, Akiko ^a   Odogawa, Reiko ^a   Tsuta, Koji ^c   Asamura, Hisao ^c   Yamamoto, Masayuki ^b,d   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer cell microenvironment; Multidrug resistant associated protein; Oxidative stress; Somatic mutation; Ubiquitin proteasome system

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CELL ENZYME; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MUTANT PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CELL PROTECTION; CELL STRESS; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVE SITE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MICROENVIRONMENT; MOLECULAR RECOGNITION; MOUTH CANCER; NEUROENDOCRINE TUMOR; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MOTIF; REGULATORY MECHANISM; SENSITIZATION; SMOKING; SOMATIC MUTATION; VALIDATION STUDY;

EID: 51649130168     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905305106     Document Type: Erratum

References (40)

1. Kasai H, Kawai K (2006) Oxidative DNA damage: Mechanisms and significance in health and disease. Antioxid Redox Signal 8:981-983.
2. Motohashi H, Yamamoto M (2007) Carcinogenesis and transcriptional regulation through Maf recognition elements. Cancer Sci 98:135-139.
3. Fahey JW, Kensler TW (2007) Role of Dietary Supplements/Nutraceuticals in Chemoprevention through Induction of Cytoprotective Enzymes. Chem Res Toxicol 20:572-576.
4. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116.
5. Ramos-Gomez M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98:3410-3415.
6. Iida K, et al. (2004) Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64:6424-6431.
7. Kobayashi A, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130-7139.
8. Kobayashi A, et al. (2006) Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26:221-229.
9. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24:10941-10953.
10. Devling TW, Lindsay CD, McLellan LI, McMahon M, Hayes JD (2005) Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl Acad Sci USA 102:7280-7285.
11. Kern JT, Hannink M, Hess JF (2007) Disruption of the keap1-containing ubiquitination complex as an antioxidant therapy. Curr Top Med Chem 7:977-983.
12. Jaiswal AK (1994) Jun and Fos regulation of NAD (P)H: Quinone oxidoreductase gene expression. Pharmacogenetics 4:1-10.
13. Gupta GP, Massague J (2006) Cancer metastasis: Building a framework. Cell 127:679-695.
14. Padmanabhan B, et al. (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21:689-700.
15. Singh A, et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3:e420.
16. Ohta T, et al. (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68:1303-1309.
17. Yamamoto T, et al. (2004) Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun 321:72-79.
18. Marzec JM, et al. (2007) Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 21:2237-2246.
19. Itoh K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76-86.
20. Tong KI, et al. (2006) Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model. Mol Cell Biol 26:2887-2900.
21. Tong KI, et al. (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 21:7511-7521.
22. Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M (2006) Structure of the Keap1: Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J 25:3605-3617.
23. Marti-Renom MA, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29:291-325.
24. Mori K, Shibanuma M, Nose K (2004) Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 64:7464-7672.
25. Petroski MD, Desharies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9 -15.
26. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism. Biol Chem 387:1311-1320.
27. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004.
28. Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789.
29. Wu LC, et al. (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440.
30. Pause A, et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, amember of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94:2156-2161.
31. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833.
32. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr., Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-10599.
33. Starita LM, Parvin JD (2006) Substrates of the BRCA1-dependent ubiquitin ligase. Cancer Biol Ther 5:137-141.
34. Wakabayashi N, et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35:238-245.
35. Reddy NM, et al. (2007) Genetic dissection of the Nrf2-dependent redox signaling regulated transcriptional programs of cell proliferation and cytoprotection. Physiol Genomics 32:74-81.
36. Bindra RS, Glazer PM (2005) Genetic instability and the tumor microenvironment: Towards the concept of microenvironment-induced mutagenesis. Mutat Res 569:75-85.
37. Adriana A, Sporn MC (2007) The tumor microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139-147.
38. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
39. Zhou J, Schmid T, Schnitzer S, Brüne B (2006) Tumor hypoxia and cancer progression. Cancer Lett 237:10-21.
40. Kim YJ, et al. (2007) Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biology. Cancer Res 67:546-554.